Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2403934 | Vaccine | 2010 | 7 Pages |
Abstract
Regulatory T cells (TReg), CD4+CD25+FOXP3+, are implicated in suppressing tumor immune responses. We analyzed peripheral blood lymphocytes (PBL) from breast cancer patients receiving a modified HLA class II HER2/neu peptide (AE37) vaccine for TReg cells and correlated their levels with vaccine-specific immune responses. The mean CD4+CD25+FOXP3+ TReg cells decreased in patients with vaccination with no significant difference in serum TGF-β levels. IFN-γ ELISPOT and DTH increased after vaccination with a good correlation between TReg cell reduction and size of DTH to AE37. The TReg cell reduction and associated immune response suggest that AE37 may be clinically useful.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Jeremy D. Gates, Guy T. Clifton, Linda C. Benavides, Alan K. Sears, Mark G. Carmichael, Matthew T. Hueman, Jarrod P. Holmes, Yusuf H. Jama, Mohamed Mursal, Athina Zacharia, Kathy Ciano, Steven Khoo, Alexander Stojadinovic, Sathibalan Ponniah,